Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Gro Egholm1, Jens Steen Olesen1,2, Eva Birgitte Leinøe3

  • 1Hjertemedicinsk Afdeling B, Odense Universitetshospital.

Ugeskrift for Laeger
|November 12, 2024
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

VIR-SAAF: a study protocol for a national decentralised randomised controlled trial of home-based sleep apnoea screening in patients with atrial fibrillation in Denmark.

BMJ open·2026
Same author

Compliance to direct oral anticoagulation therapy and clinical outcomes after catheter ablation for atrial fibrillation: a nationwide cohort study.

Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology·2026
Same author

Cyclooxygenase-1-Inhibition with Aspirin in Patients with Chronic Coronary Syndrome.

TH open : companion journal to thrombosis and haemostasis·2026
Same author

Obstructive sleep apnoea is associated with accelerated progression of diabetic kidney disease.

Diabetic medicine : a journal of the British Diabetic Association·2026
Same author

Cardiovascular pharmacotherapy in 2025.

European heart journal. Cardiovascular pharmacotherapy·2026
Same author

Reperfusion treatment strategies in acute pulmonary embolism: Study protocol for a multicenter prospective observational study in the Nordic countries (PE-NORDIC).

Thrombosis research·2026

Managing anticoagulant therapy in patients with comorbidities like kidney disease and obesity requires tailored strategies. Careful dosing adjustments are essential to balance risks and benefits in these complex cases.

Area of Science:

  • Pharmacology
  • Nephrology
  • Hepatology
  • Hematology

Background:

  • Anticoagulant therapy is crucial for many conditions but challenging in patients with comorbidities.
  • Comorbidities like kidney disease, liver disease, obesity, thrombophilia, and thrombocytopenia significantly impact anticoagulant management.
  • These conditions affect drug clearance, distribution, metabolism, and coagulation, increasing risks.

Purpose of the Study:

  • To review the challenges in managing anticoagulant therapy in patients with specific comorbidities.
  • To highlight the need for individualized therapeutic strategies in complex patient populations.
  • To provide insights into balancing the risks and benefits of anticoagulation in these groups.

Main Methods:

Related Experiment Videos

  • Literature review of studies on anticoagulant therapy in patients with kidney disease, liver disease, obesity, thrombophilia, and thrombocytopenia.
  • Analysis of how each comorbidity affects pharmacokinetic and pharmacodynamic properties of anticoagulants.
  • Synthesis of evidence regarding tailored dosing and management strategies.

    • Main Results:

    • Renal impairment alters anticoagulant drug clearance.
    • Liver disease affects the body's natural coagulation processes and drug metabolism.
    • Obesity influences drug distribution and necessitates adjusted dosing.
    • Thrombocytopenia increases bleeding risk, often requiring modified anticoagulant regimens.

    Conclusions:

    • Tailored therapeutic strategies are essential for effective and safe anticoagulant management in patients with comorbidities.
    • Individualized approaches are necessary to balance the therapeutic benefits against the increased risks of bleeding or thrombosis.
    • Further research into optimized dosing and monitoring in these complex populations is warranted.